Revenue growth reaccelerated to 10.6% year-over-year in Q3 2026 with gross margin recovering to 33.7% from a 28.9% trough, though margins remain 290 basis points below the 36.6% Q4 2024 peak as labor costs and reimbursement mix continue to pressure profitability.
Chemed Corporation (CHE) annual income statement — 30-year revenue, gross profit & net income history
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 | Dec'11 | Dec'10 | Dec'09 | Dec'08 | Dec'07 | Dec'06 | Dec'05 | Dec'04 | Dec'03 | Dec'02 | Dec'01 | Dec'00 | Dec'99 | Dec'98 | Dec'97 | Dec'96 |
|---|
| Sales/Revenue | 2.66B | 2.53B | 2.43B | 2.26B | 2.13B | 2.14B | 2.08B | 1.94B | 1.78B | 1.67B | 1.58B | 1.54B | 1.46B | 1.41B | 1.43B | 1.36B | 1.28B | 1.19B | 1.15B | 1.1B | 1.02B | 915.97M | 734.88M | 260.78M | 253.69M | 337.91M | 355.31M | 453.6M | 381.3M | 341.7M | 301.2M |
| Revenue Growth % | 5.15% | 4.06% | 7.37% | 6.06% | -0.2% | 2.87% | 7.27% | 8.75% | 6.96% | 5.7% | 2.17% | 5.98% | 3.04% | -1.17% | 5.46% | 5.89% | 7.59% | 3.59% | 4.44% | 8% | 11.2% | 24.64% | 181.8% | 2.79% | -24.92% | -4.9% | -21.67% | 18.96% | 11.59% | 13.45% | -56.92% |
| Cost of Goods Sold | 1.82B | 1.77B | 1.58B | 1.47B | 1.37B | 1.37B | 1.38B | 1.32B | 1.23B | 1.15B | 1.12B | 1.09B | 1.03B | 1.01B | 1.03B | 970.48M | 906.02M | 834.57M | 810.55M | 767.07M | 730.12M | 644.48M | 506.77M | 146.82M | 140.95M | 205.62M | 208.98M | 269.8M | 230.5M | 206M | 178.4M |
| COGS % of Revenue | - | 70.03% | 64.86% | 64.72% | 64.16% | 64.02% | 66.27% | 68.15% | 68.87% | 69.03% | 70.74% | 70.47% | 71.05% | 71.38% | 72.26% | 71.57% | 70.75% | 70.12% | 70.55% | 69.73% | 71.68% | 70.36% | 68.96% | 56.3% | 55.56% | 60.85% | 58.82% | 59.48% | 60.45% | 60.29% | 59.23% |
| Gross Profit | 842.25M | 758.34M | 854.35M | 798.82M | 765.09M | 769.8M | 701.39M | 617.43M | 555M | 516.19M | 461.45M | 455.78M | 421.61M | 404.52M | 396.72M | 385.49M | 374.53M | 355.66M | 338.39M | 332.99M | 288.46M | 271.49M | 228.11M | 113.96M | 112.74M | 132.29M | 146.33M | 183.8M | 150.8M | 135.7M | 122.8M |
| Gross Margin % | 31.65% | 29.97% | 35.14% | 35.28% | 35.84% | 35.98% | 33.73% | 31.85% | 31.13% | 30.97% | 29.26% | 29.53% | 28.95% | 28.62% | 27.74% | 28.43% | 29.25% | 29.88% | 29.45% | 30.27% | 28.32% | 29.64% | 31.04% | 43.7% | 44.44% | 39.15% | 41.18% | 40.52% | 39.55% | 39.71% | 40.77% |
| Gross Profit Growth % | - | -11.24% | 6.95% | 4.41% | -0.61% | 9.75% | 13.6% | 11.25% | 7.52% | 11.86% | 1.24% | 8.1% | 4.22% | 1.97% | 2.91% | 2.93% | 5.3% | 5.1% | 1.62% | 15.44% | 6.25% | 19.02% | 100.17% | 1.08% | -14.78% | -9.59% | -20.39% | 21.88% | 11.13% | 10.5% | -49.21% |
| Operating Expenses | 471.57M | 417.19M | 487.86M | 458.25M | 421.59M | 426.76M | 311.71M | 360.05M | 311.37M | 403.16M | 282.7M | 271.32M | 253.19M | 271.13M | 240.3M | 231.76M | 231.01M | 229.32M | 205.54M | 210.24M | 183.49M | 194.72M | 170.15M | 105.18M | 95.6M | 141.07M | 116.84M | 157M | 130.7M | 116.1M | 105.4M |
| OpEx % of Revenue | - | 16.49% | 20.07% | 20.24% | 19.75% | 19.95% | 14.99% | 18.57% | 17.47% | 24.19% | 17.93% | 17.58% | 17.39% | 19.18% | 16.8% | 17.09% | 18.04% | 19.27% | 17.89% | 19.11% | 18.01% | 21.26% | 23.15% | 40.34% | 37.68% | 41.75% | 32.88% | 34.61% | 34.28% | 33.98% | 34.99% |
| Selling, General & Admin | 446.5M | 417.19M | 424.36M | 395.12M | 358.73M | 366.73M | 330.22M | 305.71M | 271.21M | 276.65M | 248.06M | 237.82M | 222.59M | 215.56M | 208.66M | 202.26M | 201.96M | 197.43M | 175.33M | 184.06M | 161.18M | 157.26M | 147.06M | 95.36M | 85.02M | 104.72M | 103.46M | 136.9M | 113.4M | 100.9M | 93.6M |
| SG&A % of Revenue | - | 16.49% | 17.45% | 17.45% | 16.8% | 17.14% | 15.88% | 15.77% | 15.21% | 16.6% | 15.73% | 15.41% | 15.28% | 15.25% | 14.59% | 14.92% | 15.77% | 16.59% | 15.26% | 16.73% | 15.82% | 17.17% | 20.01% | 36.57% | 33.52% | 30.99% | 29.12% | 30.18% | 29.74% | 29.53% | 31.08% |
| Research & Development | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| R&D % of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Other Operating Expenses | 1000K | 0 | 63.49M | 63.13M | 62.86M | 60.04M | -18.51M | 54.34M | 40.16M | 126.5M | 34.64M | 33.5M | 30.6M | 55.56M | 31.65M | 29.5M | 29.04M | 31.89M | 30.2M | 26.18M | 22.3M | 37.46M | 23.09M | 9.82M | 10.58M | 36.34M | 13.37M | 20.1M | 17.3M | 15.2M | 11.8M |
| Operating Income | 370.86M | 338.25M | 366.49M | 340.57M | 343.5M | 343.04M | 389.68M | 257.38M | 243.63M | 113.03M | 178.75M | 184.46M | 168.42M | 133.39M | 156.42M | 153.73M | 143.52M | 126.34M | 132.86M | 122.75M | 104.98M | 79.38M | 58.11M | -7.72M | -1.55M | 18.82M | 33.47M | 26.8M | 20.1M | 19.6M | 31.3M |
| Operating Margin % | 13.94% | 13.37% | 15.07% | 15.04% | 16.09% | 16.04% | 18.74% | 13.28% | 13.67% | 6.78% | 11.34% | 11.95% | 11.56% | 9.44% | 10.94% | 11.34% | 11.21% | 10.62% | 11.56% | 11.16% | 10.31% | 8.67% | 7.91% | -2.96% | -0.61% | 5.57% | 9.42% | 5.91% | 5.27% | 5.74% | 10.39% |
| Operating Income Growth % | - | -7.71% | 7.61% | -0.85% | 0.13% | -11.97% | 51.4% | 5.64% | 115.54% | -36.76% | -3.09% | 9.52% | 26.26% | -14.72% | 1.75% | 7.11% | 13.6% | -4.9% | 8.23% | 16.93% | 32.24% | 36.62% | 852.67% | -398.06% | -108.24% | -43.77% | 24.88% | 33.33% | 2.55% | -37.38% | -5.15% |
| EBITDA | 438.45M | 403.09M | 429.54M | 401.43M | 402.67M | 402.09M | 446.26M | 302.58M | 282.5M | 148.66M | 213.39M | 217.96M | 199.02M | 162.74M | 186.94M | 183.23M | 172.56M | 154.25M | 160.36M | 148.14M | 128.78M | 102.29M | 78.29M | 2.1M | 9.03M | 40.09M | 56.91M | 46.9M | 37.4M | 34.8M | 43.1M |
| EBITDA Margin % | 16.48% | 15.93% | 17.67% | 17.73% | 18.86% | 18.8% | 21.46% | 15.61% | 15.85% | 8.92% | 13.53% | 14.12% | 13.67% | 11.51% | 13.07% | 13.51% | 13.48% | 12.96% | 13.96% | 13.47% | 12.64% | 11.17% | 10.65% | 0.81% | 3.56% | 11.87% | 16.02% | 10.34% | 9.81% | 10.18% | 14.31% |
| EBITDA Growth % | 5.44% | -6.16% | 7% | -0.31% | 0.14% | -9.9% | 47.48% | 7.11% | 90.03% | -30.33% | -2.1% | 9.52% | 22.3% | -12.95% | 2.03% | 6.18% | 11.88% | -3.81% | 8.25% | 15.03% | 25.9% | 30.66% | 3626.23% | -76.72% | -77.49% | -29.55% | 21.35% | 25.4% | 7.47% | -19.26% | -15.82% |
| D&A (Non-Cash Add-back) | 67.59M | 64.84M | 63.05M | 60.87M | 59.17M | 59.05M | 56.58M | 45.2M | 38.86M | 35.63M | 34.64M | 33.5M | 30.6M | 29.34M | 30.52M | 29.5M | 29.04M | 27.9M | 27.5M | 25.39M | 23.8M | 22.91M | 20.18M | 9.82M | 10.58M | 21.27M | 23.45M | 20.1M | 17.3M | 15.2M | 11.8M |
| EBIT | 378.55M | 357.53M | 401.25M | 353.48M | 334.26M | 352.18M | 398.35M | 266.14M | 244.59M | 121.19M | 180.77M | 183.77M | 170.97M | 138.86M | 160.54M | 154.44M | 145.79M | 132.22M | 127.53M | 113.08M | 104.98M | 76.77M | 57.95M | 8.77M | 17.14M | 15.96M | 29.49M | 26.8M | 20.1M | 19.6M | 17.4M |
| Net Interest Income | -1.96M | 7M | 12.83M | 3.16M | -4.23M | -1.49M | -1.6M | -4.02M | -4.32M | -3.85M | -3.33M | -3.36M | -8.21M | -14.19M | -13.91M | -13.46M | -11.52M | -11.18M | -11.38M | -7.94M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest Income | 2.96M | 8.74M | 14.61M | 6.27M | 355K | 377K | 757K | 513K | 671K | 427K | 383K | 281K | 0 | 847K | 809K | 426K | 444K | 423K | 743K | 3.3M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 4.92M | 1.75M | 1.78M | 3.11M | 4.58M | 1.87M | 2.35M | 4.54M | 4.99M | 4.27M | 3.71M | 3.65M | 8.21M | 15.04M | 14.72M | 13.89M | 11.96M | 11.6M | 5.99M | 11.24M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Income/Expense | 11.46M | 17.53M | 32.97M | 9.8M | -13.82M | 7.28M | 6.31M | 4.23M | -4.03M | 3.88M | -1.7M | -4.33M | -5.67M | -9.56M | -12.94M | -13.17M | -9.69M | -5.72M | -10.51M | -20.92M | -14.7M | -24.73M | -21.02M | 7.67M | -18.42M | -29.14M | -2.54M | 4.2M | 12M | 8.3M | 11M |
| Pretax Income | 382.32M | 355.78M | 399.46M | 350.37M | 329.68M | 350.31M | 395.99M | 261.61M | 239.6M | 116.92M | 177.05M | 180.13M | 162.75M | 123.83M | 145.82M | 140.56M | 133.83M | 120.62M | 122.34M | 101.84M | 90.28M | 57.28M | 37.09M | 1.25M | -1.27M | -10.06M | 33.25M | 31M | 32.1M | 27.9M | 53.6M |
| Pretax Margin % | 14.37% | 14.06% | 16.43% | 15.47% | 15.44% | 16.38% | 19.04% | 13.5% | 13.44% | 7.01% | 11.23% | 11.67% | 11.18% | 8.76% | 10.2% | 10.37% | 10.45% | 10.13% | 10.65% | 9.26% | 8.86% | 6.25% | 5.05% | 0.48% | -0.5% | -2.98% | 9.36% | 6.83% | 8.42% | 8.17% | 17.8% |
| Income Tax | 99.92M | 90.54M | 97.47M | 77.86M | 80.06M | 81.76M | 76.52M | 41.69M | 34.06M | 18.74M | 68.31M | 69.85M | 63.44M | 46.6M | 56.52M | 54.58M | 52M | 46.58M | 50.24M | 39.06M | 32.56M | 19.58M | 13.8M | 4.75M | 6.85M | -3.36M | 12.66M | 11.3M | 12.2M | 10.8M | 21.9M |
| Effective Tax Rate % | 26.13% | 25.45% | 24.4% | 22.22% | 24.28% | 23.34% | 19.32% | 15.93% | 14.21% | 16.03% | 38.58% | 38.78% | 38.98% | 37.63% | 38.76% | 38.83% | 38.85% | 38.62% | 41.06% | 38.36% | 36.07% | 34.18% | 37.2% | 379.92% | -537.02% | 33.41% | 38.09% | 36.45% | 38.01% | 38.71% | 40.86% |
| Net Income | 282.4M | 265.24M | 302M | 272.51M | 249.62M | 268.55M | 319.47M | 219.92M | 205.54M | 98.18M | 108.74M | 110.27M | 99.32M | 77.23M | 89.3M | 85.98M | 81.83M | 73.78M | 71.02M | 63.98M | 50.65M | 35.82M | 27.51M | -3.44M | -1.81M | -10.38M | 20.58M | 19.7M | 19.9M | 30.3M | 32.3M |
| Net Margin % | 10.61% | 10.48% | 12.42% | 12.03% | 11.69% | 12.55% | 15.36% | 11.34% | 11.53% | 5.89% | 6.9% | 7.14% | 6.82% | 5.46% | 6.24% | 6.34% | 6.39% | 6.2% | 6.18% | 5.82% | 4.97% | 3.91% | 3.74% | -1.32% | -0.71% | -3.07% | 5.79% | 4.34% | 5.22% | 8.87% | 10.72% |
| Net Income Growth % | 1.29% | -12.17% | 10.82% | 9.17% | -7.05% | -15.94% | 45.26% | 7% | 109.36% | -9.72% | -1.39% | 11.03% | 28.6% | -13.52% | 3.87% | 5.07% | 10.91% | 3.9% | 11.01% | 26.31% | 41.42% | 30.19% | 900.93% | -89.46% | 82.53% | -150.4% | 4.49% | -1% | -34.32% | -6.19% | 39.83% |
| Net Income (Continuing) | 282.4M | 265.24M | 302M | 272.51M | 249.62M | 268.55M | 319.47M | 219.92M | 205.54M | 98.18M | 108.74M | 110.27M | 99.32M | 77.23M | 89.3M | 85.98M | 81.83M | 74.04M | 72.11M | 62.77M | 57.72M | 36.23M | 19.09M | 11.19M | 11.11M | -10.74M | 18.64M | 19.7M | 19.9M | 17.1M | 25.1M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 8.33M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 10.8M |
| EPS (Diluted) | 21.50 | 18.42 | 19.89 | 17.93 | 16.53 | 16.85 | 19.48 | 13.31 | 12.23 | 5.86 | 6.48 | 6.33 | 5.57 | 4.16 | 4.62 | 4.10 | 3.55 | 3.24 | 3.04 | 2.55 | 1.90 | 1.36 | 1.12 | -0.17 | -0.09 | -0.53 | 1.00 | 0.93 | 0.99 | 1.51 | 1.63 |
| EPS Growth % | 10.58% | -7.39% | 10.93% | 8.47% | -1.9% | -13.5% | 46.36% | 8.83% | 108.7% | -9.57% | 2.37% | 13.64% | 33.89% | -9.96% | 12.68% | 15.49% | 9.57% | 6.58% | 19.22% | 34.21% | 39.71% | 21.43% | 758.82% | -85.39% | 82.7% | -153% | 7.53% | -6.06% | -34.44% | -7.36% | 38.14% |
| EPS (Basic) | - | 18.42 | 20.10 | 18.11 | 16.72 | 17.14 | 20.02 | 13.77 | 12.80 | 6.11 | 6.64 | 6.54 | 5.79 | 4.24 | 4.72 | 4.19 | 3.62 | 3.29 | 3.08 | 2.61 | 1.94 | 1.40 | 1.14 | -0.17 | -0.09 | -0.53 | 1.01 | 0.93 | 0.99 | 1.52 | 1.65 |
| Diluted Shares Outstanding | 13.13M | 14.4M | 15.19M | 15.2M | 15.1M | 15.94M | 16.4M | 16.53M | 16.8M | 16.74M | 16.79M | 17.42M | 17.84M | 18.59M | 19.34M | 20.95M | 23.03M | 22.74M | 23.37M | 25.08M | 26.67M | 26.3M | 24.64M | 19.91M | 19.77M | 19.43M | 19.85M | 21.03M | 20.2M | 20.03M | 19.82M |
| Basic Shares Outstanding | 13.06M | 14.4M | 15.02M | 15.05M | 14.93M | 15.67M | 15.96M | 15.97M | 16.06M | 16.06M | 16.38M | 16.87M | 17.16M | 18.2M | 18.92M | 20.52M | 22.59M | 22.45M | 23.06M | 24.52M | 26.12M | 25.55M | 24.12M | 19.85M | 19.72M | 19.43M | 19.67M | 20.94M | 20.12M | 19.88M | 19.58M |
| Dividend Payout Ratio | - | 11.95% | 8.97% | 8.62% | 8.82% | 8.2% | 6.6% | 9% | 9.08% | 17.69% | 15.12% | 14.15% | 14.35% | 18.32% | 14.59% | 14.58% | 14.52% | 11.06% | 7.81% | 9.2% | 12.48% | 17.23% | 20.78% | - | - | - | 19.54% | 114.21% | 109.05% | 69.31% | 63.16% |
Quick answers to the most common questions about buying CHE stock.
For fiscal year 2025, Chemed Corporation (CHE) reported total revenue of $2.53B. This represents a 740.0% increase compared to $301.2M in 1996.
Chemed Corporation (CHE) is profitable, generating $265.2M in net income for the fiscal year ending 2025 with a net profit margin of 10.5%.
Chemed Corporation (CHE) reported an operating income of $338.2M, resulting in an operating profit margin of 13.4%. This margin reflects the operational efficiency of the business before interest and taxes.
Chemed Corporation (CHE) generated $758.3M in gross profit for the year, representing a gross profit margin of 30.0%. This demonstrates the company's core pricing power and production efficiency.
Key Metrics
Top Statement Risk
Labor inflation vs. reimbursement caps
Metrics are mathematically derived from official filings.
Revenue Growth Reaccelerates After Mid-Cycle Pause
According to Chemed's quarterly income statements, revenue growth rebounded to 10.6% year-over-year in Q3 2026, up from just 1.6% in Q1 2026, suggesting the mid-2025 deceleration proved transitory as sequential revenue climbed from $618.8M to $690.9M over five quarters.
The YoY growth trajectory reveals a pronounced V-shaped pattern: near-zero growth in Q4 2025 (-0.1%) and Q1 2026 (1.6%) bracketed a recovery to high-single-digit rates in the most recent two quarters. This volatility likely reflects a combination of base effects from a strong Q1 2025 comparison and potential timing dynamics in VITAS patient admissions, alongside Roto-Rooter's weather-dependent seasonal demand. Investors should monitor whether the current growth rate of 8–10% proves sustainable or whether the mid-cycle pause presages renewed deceleration once favorable comparisons normalize.
Gross Margin Recovery Masks Structural Cost Pressures
As reported in Chemed's financial statements, gross margins contracted from a peak of 36.6% in Q4 2024 to a trough of 28.9% in Q3 2025 before recovering to 33.7% in Q3 2026, reflecting meaningful margin volatility driven by labor costs and reimbursement mix.
The 770 basis point swing from peak to trough within approximately three quarters is unusually wide for a business with a large recurring revenue base, suggesting that external cost pressures — particularly wage inflation in hospice staffing and technician compensation at Roto-Rooter — have materially impacted the cost of revenue line. While Q3 2026's recovery to 33.7% is encouraging, margins remain roughly 290 basis points below the Q4 2024 peak, indicating the recovery may be incomplete. The persistent gap between current and peak margins suggests that Medicare reimbursement constraints and ongoing healthcare labor tightness may be establishing a structurally lower margin ceiling than historically observed.
SG&A Discipline Supports Operating Leverage Recovery
Based on Chemed's reported figures, SG&A spending held broadly flat at $99.6M to $115.2M across ten quarters while revenue expanded from $595.9M to $690.9M, indicating overhead leverage as SG&A declined from roughly 16.7% of revenue to 16.1% in Q3 2026.
The relatively contained SG&A trajectory — rising only modestly even as revenue grew nearly 16% over the period — suggests management has maintained tight control over corporate overhead, which is consistent with the company's historical capital allocation discipline. Operating margins nonetheless swung from 17.8% in Q4 2024 to 11.0% in Q2 2025 before recovering to 14.0% in Q3 2026, implying that the operating margin compression was driven primarily by gross profit dynamics rather than overhead bloat. This distinction matters: if SG&A leverage is genuinely structural, then any further gross margin recovery should translate disproportionately into operating income expansion.
SBC Volatility Obscures Earnings Trajectory
As disclosed in Chemed's quarterly filings, stock-based compensation has exhibited unusual volatility, swinging from -$15.2M in Q3 2025 to $23.5M in Q4 2025, creating significant noise in net income and complicating any assessment of underlying operational earnings quality across reporting periods.
The erratic SBC figures — ranging from -$15.2M to $23.5M — introduce substantial quarter-to-quarter distortion in net income comparisons, making it difficult to isolate true operating performance from compensation-related accounting adjustments. For instance, Q4 2025's $76.8M net income was earned alongside $23.5M of SBC, while Q3 2026's $71.6M net income reflected a -$3.7M SBC charge, suggesting that adjusted earnings on a consistent basis may tell a different story than headline EPS. Analysts should consider normalizing for SBC when evaluating the durability of the reported EPS recovery from $4.46 in Q3 2025 to $5.49 in Q3 2026, as the underlying operational trajectory may be smoother than headline numbers suggest.
Margin Recovery Faces Structural Reimbursement Ceiling
Despite the recent gross margin recovery to 33.7% in Q3 2026, Chemed's margins remain 290 basis points below the Q4 2024 peak, and persistent healthcare labor inflation combined with Medicare per-diem rate constraints may permanently limit the company's ability to recapture prior profitability levels.
The most compelling bear case centers on the observation that each sequential margin recovery since mid-2025 has failed to reach the prior cycle's high — 33.5% in Q1 2025 versus 36.6% in Q4 2024, and 33.7% in Q3 2026 versus 34.6% in Q2 2024 — suggesting a potentially declining margin ceiling consistent with structural cost absorption challenges in VITAS's labor-intensive model. Additionally, the Q3 2026 EPS of $5.49, while encouraging, still fell short of Q4 2024's $6.02, raising the question of whether the recent re-acceleration in revenue growth is being fully captured at the earnings line or partially offset by a permanently elevated cost base that warrants closer scrutiny in subsequent filings.